Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial investigates a genetically engineered lymphocyte therapy given after peripheral blood stem cell transplant in patients with high-risk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-12-21